Favorable outcome of neonatal cerebrospinal fluid shunt-associated Candida meningitis with caspofungin

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 5, 2013, Pages 2391-2393

  Jans, Jop ^a   Brüggemann, Roger J M ^a   Christdmann, V ^a   Verweij, Paul E ^a   Warris, Adilia ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIBIOTIC AGENT; C REACTIVE PROTEIN; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE;

ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BRAIN HEMORRHAGE; BRAIN VENTRICLE DILATATION; BROTH DILUTION; CANDIDA ALBICANS; CANDIDA MENINGITIS; CASE REPORT; CAUCASIAN; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CEREBROSPINAL FLUID SHUNTING; CESAREAN SECTION; CREATININE BLOOD LEVEL; DEVICE REMOVAL; DRUG BLOOD LEVEL; DRUG EXPOSURE; FOLLOW UP; GESTATIONAL AGE; HUMAN; HYDROCEPHALUS; LEUKOCYTE COUNT; LUMBAR PUNCTURE; MALE; MINIMUM INHIBITORY CONCENTRATION; NECROTIZING ENTEROCOLITIS; NEWBORN; NUCLEAR MAGNETIC RESONANCE IMAGING; OFF LABEL DRUG USE; OPHTHALMOSCOPY; PLEOCYTOSIS; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY FAILURE; SHUNT INFECTION; SIDE EFFECT; STAPHYLOCOCCUS WARNERI; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UREAPLASMA UREALYTICUM; URINE CULTURE;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; CEREBROSPINAL FLUID SHUNTS; ECHINOCANDINS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; MALE; TREATMENT OUTCOME;

EID: 84876232679     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02085-12     Document Type: Article

References (15)

1. Benjamin DK, Jr, Stoll BJ, Fanaroff AA, McDonald SA, Oh W, Higgins RD, Duara S, Poole K, Laptook A, Goldberg R. 2006. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 117:84-92.
2. Uppuluri P, Srinivasan A, Ramasubramanian A, Lopez-Ribot JL. 2011. Effects of fluconazole, amphotericin B, and caspofungin on Candida albicans biofilms under conditions of flow and on biofilm dispersion. Antimicrob. Agents Chemother. 55:3591-3593.
3. Fiori B, Posteraro B, Torelli R, Tumbarello M, Perlin DS, Fadda G, Sanguinetti M. 2011. In vitro activities of anidulafungin and other antifungal agents against biofilms formed by clinical isolates of different Candida and Aspergillus species. Antimicrob. Agents Chemother. 55:3031-3035.
4. Katragkou A, Chatzimoschou A, Simitsopoulou M, Dalakiouridou M, Diza-Mataftsi E, Tsantali C, Roilides E. 2008. Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. Antimicrob. Agents Chemother. 52:357-360.
5. Kucharikova S, Tournu H, Holtappels M, Van Dijck P, Lagrou K. 2010. In vivo efficacy of anidulafungin against mature Candida albicans biofilms in a novel rat model of catheter-associated candidiasis. Antimicrob. Agents Chemother. 54:4474-4475.
6. Odio CM, Araya R, Pinto LE, Castro CE, Vasquez S, Alfaro B, Saenz A, Herrera ML, Walsh TJ. 2004. Caspofungin therapy of neonates with invasive candidiasis. Pediatr. Infect. Dis. J. 23:1093-1097.
7. Saez-Llorens X, Macias M, Maiya P, Pineros J, Jafri HS, Chatterjee A, Ruiz G, Raghavan J, Bradshaw SK, Kartsonis NA, Sun P, Strohmaier KM, Fallon M, Bi S, Stone JA, Chow JW. 2009. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob. Agents Chemother. 53:869-875.
8. Warn PA, Livermore J, Howard S, Felton TW, Sharp A, Gregson L, Goodwin J, Petraitiene R, Petraitis V, Cohen-Wolkowiez M, Walsh TJ, Benjamin DK, Jr, Hope WW. 2012. Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach. Antimicrob. Agents Chemother. 56:708-714.
9. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). 2008. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin. Microbiol. Infect. 14:398-405.
10. Arendrup MC, Rodriguez-Tudela JL, Lass-Florl C, Cuenca-Estrella M, Donnelly JP, Hope W, European Committee on Antimicrobial Susceptibility Testing - Subcommittee on Antifungal Susceptibility Testing. 2011. EUCAST technical note on anidulafungin. Clin. Microbiol. Infect. 17:E18-E20.
11. Hsue G, Napier JT, Prince RA, Chi J, Hospenthal DR. 2004. Treatment of meningeal coccidioidomycosis with caspofungin. J. Antimicrob. Chemother. 54:292-294.
12. Okugawa S, Ota Y, Tatsuno K, Tsukada K, Kishino S, Koike K. 2007. A case of invasive central nervous system aspergillosis treated with micafungin with monitoring of micafungin concentrations in the cerebrospinal fluid. Scand. J. Infect. Dis. 39:344-346.
13. Neely M, Jafri HS, Seibel N, Knapp K, Adamson PC, Bradshaw SK, Strohmaier KM, Sun P, Bi S, Dockendorf MF, Stone JA, Kartsonis NA. 2009. Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob. Agents Chemother. 53:1450-1456.
14. Li CC, Sun P, Dong Y, Bi S, Desai R, Dockendorf MF, Kartsonis NA, Ngai AL, Bradshaw S, Stone JA. 2011. Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients. Antimicrob. Agents Chemother. 55:2098-2105.
15. Hope WW, Mickiene D, Petraitis V, Petraitiene R, Kelaher AM, Hughes JE, Cotton MP, Bacher J, Keirns JJ, Buell D, Heresi G, Benjamin DK, Jr, Groll AH, Drusano GL, Walsh TJ. 2008. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J. Infect. Dis. 197:163-171.